Oregon, US: Researchers at Oregon State University (OSU) have made a major breakthrough in cancer therapy with the development of a new nanomaterial that can selectively kill cancer cells while sparing healthy tissues.
Led by Oleh and Olena Taratula and Chao Wang from the OSU College of Pharmacy, the study—published this week in Advanced Functional Materials—introduces a nanomaterial that triggers two chemical reactions inside cancer cells.
These reactions generate reactive oxygen species (ROS), inducing oxidative stress that destroys malignant cells.
Unlike conventional chemodynamic therapy (CDT), which typically produces either hydroxyl radicals or singlet oxygen and often lacks sufficient catalytic activity, the new nanomaterial can generate both ROS types simultaneously, significantly enhancing therapeutic efficiency.
“Compared to healthy tissues, malignant tumors are more acidic and have higher hydrogen peroxide concentrations,” the researchers explained. “Our nanoagent takes advantage of this unique tumor microenvironment to completely eradicate cancer cells.”
In preclinical tests on mice implanted with human breast cancer cells, the nanomaterial accumulated efficiently in tumors, generated robust ROS, and led to total tumor regression without causing systemic toxicity. Researchers also observed long-term prevention of cancer recurrence, highlighting the treatment’s potential durability.
The team plans to further evaluate the nanomaterial against multiple cancer types, including aggressive pancreatic cancer, to confirm its broad applicability across various malignancies before human clinical trials.
This discovery marks a significant step forward in safer and more effective cancer treatment, potentially transforming the future of chemodynamic therapy.
